{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:27:41Z","timestamp":1794547661719,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eclinm.2025.103476","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T08:40:11Z","timestamp":1756543211000},"page":"103476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souphatta","family":"Sasorith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6854","authenticated-orcid":false,"given":"Karen","family":"Raraigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2025.103476_bib1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis F508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.eclinm.2025.103476_bib2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103476_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single F508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"6617","key":"10.1016\/j.eclinm.2025.103476_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science (New York, NY)"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103476_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. food and drug administration's experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103476_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01146-2024","article-title":"Impact of the expanded label for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with no F508del variant in the USA","volume":"64","author":"Cromwell","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eclinm.2025.103476_bib7","article-title":"The French compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103476_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103476_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103476_bib10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Highsmith","year":"1994","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.eclinm.2025.103476_bib11","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1074\/jbc.274.31.21873","article-title":"C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation","volume":"274","author":"Haardt","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103476_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103476_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2022.12.003","article-title":"The multi-faceted nature of 15 CFTR exonic variations: impact on their functional classification and perspectives for therapy","volume":"22","author":"Bergougnoux","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103476_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/arm92040026","article-title":"Cystic fibrosis: understanding cystic fibrosis transmembrane regulator mutation classification and modulator therapies","volume":"92","author":"Anwar","year":"2024","journal-title":"Adv Respir Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103476_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103476_bib16","doi-asserted-by":"crossref","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch Pediatr"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103476_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41434-022-00347-0","article-title":"Splicing mutations in the CFTR gene as therapeutic targets","volume":"29","author":"Deletang","year":"2022","journal-title":"Gene Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103476_bib18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103476_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/humu.23276","article-title":"CFTR-France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants","volume":"38","author":"Claustres","year":"2017","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103476_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007723","article-title":"Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis","volume":"14","author":"Sharma","year":"2018","journal-title":"PLoS Genet"},{"key":"10.1016\/j.eclinm.2025.103476_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.omtn.2023.06.020","article-title":"Protospacer modification improves base editing of a canonical splice site variant and recovery of CFTR function in human airway epithelial cells","volume":"33","author":"Joynt","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103476_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103476_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001153","article-title":"Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier","volume":"6","author":"Hinzpeter","year":"2010","journal-title":"PLoS Genet"},{"issue":"6450","key":"10.1016\/j.eclinm.2025.103476_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1126\/science.aaw0553","article-title":"Making precision medicine personal for cystic fibrosis","volume":"365","author":"Manfredi","year":"2019","journal-title":"Science (New York, NY)"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103476_bib25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of Elexacaftor-Tezacaftor-Ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103476_bib26","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/humu.23821","article-title":"First estimate of the scale of canonical 5' splice site GT>GC variants capable of generating wild-type transcripts","volume":"40","author":"Lin","year":"2019","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103476_bib27","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103476_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:09:52Z","timestamp":1794546592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025004092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"alternative-id":["S2589537025004092"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103476","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103476"}}